Core Insights - Jacob Funds released its fourth-quarter 2025 investor letter, noting a slight correction in equity markets in November despite robust economic growth throughout the year [1] - Divergent data on consumer spending and the labor market has raised doubts about future economic projections, a trend that has become common in recent years [1] - The Fund's strategy indicates that moderation in AI tech companies may benefit small companies, potentially leading to expansion in valuation multiples and favorable performance compared to peers [1] Company Focus: Prime Medicine, Inc. - Prime Medicine, Inc. (NASDAQ:PRME) is highlighted as a biotechnology company specializing in gene editing technology, with a market capitalization of $597.49 million [2] - As of February 17, 2026, Prime Medicine's stock closed at $3.31 per share, with a one-month return of -17.46% and a 12-month increase of 0.76% [2] - Jacob Funds added Prime Medicine to its portfolio, expressing confidence in its gene editing technology and the potential for significant upside if the technology proves viable [3] - The company acknowledges challenges in the gene therapy field, including safety, durability, and cost, but remains optimistic about the potential for effective cures for chronic and deadly diseases [3] - Promising efficacy and safety signals were observed in Prime Medicine's first clinical trial, indicating early positive developments in its gene editing capabilities [3]

Core Insights - Vanda Pharmaceuticals reported a quarterly loss of $0.46 per share, significantly better than the Zacks Consensus Estimate of a loss of $2.18, representing an earnings surprise of +78.85% [1] - The company posted revenues of $57.22 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 2.78%, but showing an increase from $53.19 million year-over-year [2] - Vanda shares have underperformed the market, losing about 15.9% since the beginning of the year compared to the S&P 500's gain of 1.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.24 on revenues of $64 million, and for the current fiscal year, it is -$1.47 on revenues of $275.85 million [7] - The estimate revisions trend for Vanda was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Vanda belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1 - Prime Drink Group Corp. has secured exclusive licenses for the Beach Day Every Day ("BDED") trademarks, allowing the company to produce and commercialize ready-to-drink beverages and low-calorie cola beverages in North America, excluding Québec, for a five-year term [1] - The licensing agreement is seen as a significant step in expanding the BDED brand in North America, with the company positioned for faster growth and long-term success [2] - The company has decided not to proceed with the acquisition of a 70% interest in 9375-4208 Québec Inc., which was primarily focused on the Relax Downlow brand [3] Group 2 - Prime Drink Group Corp. is based in Québec and aims to become a leading diversified holding company in the beverage, influencer media, and hospitality sectors [4]

Group 1 - Prime Drink Group Corp. announced a first closing of its non-brokered private placement offering, raising gross proceeds of $450,000 by issuing 7,500,015 common shares and 7,500,015 warrants, with each warrant priced at $0.06 per share for three years [1] - The net proceeds from the Unit Offering will be used to develop the company's business and for general working capital purposes [2] - The securities issued are subject to a resale restriction of four months and one day from the issuance date, pending final approval from the Canadian Securities Exchange and other regulatory approvals [2] Group 2 - The company granted 3,500,000 stock options to a director and a consultant, allowing them to acquire the same number of common shares at a price of $0.06 per share for three years [3] - Prime Drink Group Corp. is based in Québec and aims to become a leading diversified holding company in the beverage, influencer media, and hospitality sectors [4]

Core Insights - Prime Medicine Inc. (NASDAQ:PRME) is recognized as a promising biotech penny stock, with LifeSci Capital initiating coverage and assigning an Outperform rating along with a $6 price target, emphasizing its innovative gene editing treatments for high unmet medical needs [1][2] Group 1: Company Overview - Prime Medicine Inc. focuses on delivering genetic therapies through gene editing technology to address a wide range of diseases in the US [3] Group 2: Clinical Developments - The company announced Phase 1/2 clinical data for its investigational therapy PM359, published in the New England Journal of Medicine, demonstrating the first-in-human safety and efficacy of Prime Editing [1] - In the clinical trial involving PM359, two patients (one adult and one pediatric) with chronic granulomatous disease (CGD) showed rapid neutrophil and platelet engraftment, achieving 69% and 83% dihydrorhodamine-positive neutrophils by Day 30, significantly exceeding the 20% threshold for clinical benefit [2] - Both participants in the trial have remained free of new CGD-related complications, indicating successful long-term gene correction in hematopoietic stem cells [2] Group 3: Market Potential - LifeSci Capital expressed optimism regarding the commercial and clinical opportunities for Prime Medicine, particularly in the treatment landscapes of Wilson's disease and alpha-1 antitrypsin deficiency (AATD) [1]

Group 1 - Prime Medicine, Inc. (NASDAQ:PRME) is recognized as one of the 12 best genomics stocks to invest in [1] - The New England Journal of Medicine published Phase 1/2 clinical results for PM359, an experimental autologous hematopoietic stem cell therapy for p47phox chronic granulomatous condition, showing promising safety and effectiveness [2] - In the Phase 1/2 trial, two patients exhibited fast neutrophil engraftment with 69% and 83% dihydrorhodamine-positive neutrophils by Day 30, and no new CGD-related problems were reported post-infusion [2] Group 2 - LifeSci Capital initiated coverage of Prime Medicine, Inc. with an Outperform rating and a $6 price target, highlighting the company's potential in gene editing treatments for conditions with significant unmet demand [3] - The firm expressed optimism regarding the potential of Prime Medicine's treatments for Wilson's disease and alpha-1 antitrypsin deficiency [3] - Prime Medicine focuses on providing genetic medicines through gene editing technology known as Prime Editing [4]

Group 1: Biotech Sector Overview - The healthcare sector has become the top-performing sector over the last 3 months as investors rotate away from high-valuation tech and AI stocks [1] - The biotech sub-sector is highlighted as particularly interesting for 2026, with the XBI (SPDR S&P Biotech ETF) serving as a proxy for small and mid-cap companies [1] - A historic shift in sentiment is observed, with the XBI achieving a rare streak of 6 consecutive months of positive returns [1] Group 2: Market Dynamics and Investor Sentiment - Investors are moving towards healthcare due to concerns over concentrated tech positions and favorable valuations in healthcare [1] - Clarity around drug pricing is identified as a major positive catalyst for pharmaceutical and biotech companies [1] - A surge in M&A activity is noted, with over 20 deals worth more than $500 million in 2025 alone [1] Group 3: Small-Cap Market Insights - The small-cap trade is expected to continue, but leadership within this category is set to change, focusing back on earnings growth [2] - The recent rally in the Russell index has been led by speculative areas, including biotech companies, which currently do not produce earnings [2] - Approximately 30% of trading volume is in stocks priced under $5, indicating young investors' interest in speculative names [2] Group 4: Biotech Penny Stocks - Rezolute Inc. (NASDAQ:RZLT) is identified as a top biotech penny stock with an average upside potential of 68.54% [7] - Prime Medicine Inc. (NASDAQ:PRME) is also highlighted, with an average upside potential of 71.43% and recent positive clinical data [11] - Both companies are involved in innovative treatments, with Rezolute focusing on congenital hyperinsulinism and Prime Medicine on gene editing therapies [10][14]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Group 1: Premarket Gainers - AlphaTime Acquisition Corp (ATMC) has seen a remarkable increase of 602%, trading at $104.70 [3] - Exicure, Inc. (XCUR) is up 70%, currently priced at $8.98 [3] - Vor Biopharma Inc. (VOR) has risen by 53%, trading at $12.83 [3] - Other notable gainers include AlphaVest Acquisition Corp (ATMV) up 20% at $9.45, Mama's Creations, Inc. (MAMA) up 16% at $13.00, and Ares Management Corporation (ARES) up 8% at $178.34 [3] Group 2: Premarket Losers - Top Wealth Group Holding Limited (TWG) has experienced a significant decline of 48%, trading at $11.31 [4] - Cemtrex, Inc. (CETX) is down 16%, currently at $5.86 [4] - Gulf Resources, Inc. (GURE) has decreased by 14%, trading at $4.70 [4] - Other notable losers include JX Luxventure Group Inc. (JXG) down 10% at $4.58, HWH International Inc. (HWH) down 10% at $2.08, and MetaVia Inc. (MTVA) down 8% at $10.50 [4]

Core Insights - Prime Medicine, Inc. is participating in the 8th Annual Evercore Healthcare Conference on December 2, 2025, with CEO Allan Reine as a speaker [1] - The company focuses on developing a new class of one-time curative genetic therapies using its proprietary Prime Editing platform [3] Company Overview - Prime Medicine is a biotechnology company dedicated to gene editing therapies, utilizing a precise and efficient technology that minimizes unwanted DNA modifications [3] - The Prime Editing platform has the potential to repair various genetic mutations across multiple tissues, organs, and cell types, unlocking opportunities for thousands of potential indications [3] Therapeutic Programs - The company is advancing a diversified portfolio of investigational therapeutic programs in core areas such as liver, lung, immunology, and oncology [4] - Each program targets diseases with well-understood biology and a clear clinical development path, aiming to expand into additional opportunities over time [4] - Prime Medicine plans to leverage the versatility of its Prime Editing platform to address a wide range of genetic, immunological, and infectious diseases, impacting millions of people [4]

Core Insights - The article compares Liminatus Pharma and Prime Medicine, focusing on their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, and profitability. Profitability - Liminatus Pharma's profitability metrics are not available, while Prime Medicine shows significant negative margins with a net margin of -3,301.64%, return on equity of -163.51%, and return on assets of -61.21% [2][4]. Earnings & Valuation - Liminatus Pharma has higher earnings per share at -$0.12 compared to Prime Medicine's -$1.44. However, Prime Medicine has a gross revenue of $2.98 million. Liminatus Pharma trades at a lower price-to-earnings ratio of -5.99, indicating it is more affordable than Prime Medicine, which has a price-to-earnings ratio of -2.52 [4]. Institutional & Insider Ownership - Prime Medicine has a strong institutional ownership of 70.4% and insider ownership of 22.7%, suggesting confidence from large investors in its long-term growth potential [5]. Analyst Ratings - Both Liminatus Pharma and Prime Medicine have received one sell rating each, with no hold or buy ratings, resulting in a rating score of 1.00 for both companies [7]. Company Background - Liminatus Pharma is a pre-clinical-stage immuno-oncology company focused on developing immune-modulating cancer therapies, founded in November 2020 and headquartered in La Palma, CA [10]. - Prime Medicine is a biotechnology company specializing in one-time curative genetic therapies using Prime Editing technology, which aims to address a wide range of diseases [12][13].